Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations
Open Access
- 1 August 2020
- journal article
- review article
- Published by Wiley in ESC Heart Failure
- Vol. 7 (4), 1477-1487
- https://doi.org/10.1002/ehf2.12701
Abstract
Aims Whereas up to about half of patients with heart failure with reduced ejection fraction (HFrEF) report no or only mild symptoms and are considered as clinically stable, the progressive nature of HFrEF, often silent, renders clinical stability a misleading situation, especially if disease progression is unrecognized. We highlight the challenges in the definition of clinical stability and mild symptomatic status in HFrEF, outline clinical characteristics and available diagnostic tools, and discuss evidence and gaps in the current guidelines for the management of these patients. Methods and Results This is a state-of-the-art review that focuses on clinical, diagnostic, and therapeutic aspects in mildly symptomatic HFrEF patients; summarizes the challenges; and proposes directions for future research in this group of patients. The New York Heart Association classification has been widely used as a measure of prognosis in HFrEF, but it lacks objectivity and reproducibility in terms of symptoms assessment. The definition of clinical stability as described in current guidelines is vague and may often lead to underdiagnosis of disease progression in patients who appear to be 'stable' but in fact are at an increased risk of clinical worsening, hospitalization, or death. Although an increasing number of clinical trials proved that the efficacy of HFrEF therapies was unrelated to the symptomatic status of patients and led to their implementation early in the course of the disease, clinical inertia in terms of under-prescription or underdosing of guideline-recommended medications in mildly symptomatic HFrEF patients is still a challenging issue to deal with. Conclusions Mildly symptomatic status in a patient with HFrEF is very frequent; it should not be ignored and should not be regarded as an index of disease stability. The application of risk scores designed to predict mortality and mode of death should be engaged among mildly symptomatic patients, not only to identify the most suitable HF candidates for cardioverter defibrillator implantation, but also to identify patients who might benefit from early intensification of medical treatment before the implementation of more interventional approaches.This publication has 61 references indexed in Scilit:
- Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) studyEuropean Heart Journal, 2013
- The Diagnostic Value of Physical Examination and Additional Testing in Primary Care Patients With Suspected Heart FailureCirculation, 2011
- Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAmerican Heart Journal, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsThe New England Journal of Medicine, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- A Comparison of Patient and Physician-Rated New York Heart Association Class in a Community-Based Heart Failure ClinicJournal of Cardiac Failure, 2008
- Prediction of Mode of Death in Heart FailureCirculation, 2007
- Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failureHeart, 2007
- Stage B Heart FailureCirculation, 2006
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureThe New England Journal of Medicine, 2001